A wide array of biomarkers is being investigated as predictors of prostate cancer (PCa) diagnosis and recurrence. We compared the expression of a small panel of these biomarkers as a function of race among men undergoing radical prostatectomy (RP). Prostate needle biopsy specimens from 131 patients treated with RP at the Durham Veterans Affairs Medical Center were hematoxylin and eosin stained and immunofluorescent assayed for a-methylacyl CoA racemase (AMACR), androgen receptor (AR) and Ki67. Proprietary image analysis was used to identify six biometric feature combinations that were significantly associated with progression in a previous study. Analysis of population characteristics, stratified by race, was performed using rank-sum and v 2 -test. The effect of race on expression of these biomarker profiles was analyzed using multivariate linear regression. All six biomarker features were expressed at higher levels in black men than white men, with Norm AR (P ¼ 0.006) and Ki67 (P ¼ 0.02) attaining statistical significance. On multivariate analysis, all markers were expressed at higher levels in black men, with Norm AR (P ¼ 0.001), Ki67 (P ¼ 0.007) and Ki67/lum (P ¼ 0.022) reaching significance. These data support the hypothesis that PCa may be biologically more aggressive among black men.
Introduction
Prostate cancer (PCa) is the most common non-cutaneous malignancy in men, with a lifetime incidence of one in six. 1 This rate is even higher in black men, with an incidence almost twice as high as white men. 2 Additionally, black men have higher PSA levels at time of diagnosis, [3] [4] [5] larger tumor volumes at time of radical prostatectomy (RP), [4] [5] [6] an increased prevalence of highgrade disease, 6 and a higher mortality rate from their PCa. 2 These observations are likely influenced in part by socioeconomic factors and non-financial barriers to care; however, these disparities only explain a portion of the overall picture. Studies have shown, for example, that socioeconomic status alone cannot explain why black men die from PCa at a higher rate than their white counterparts. 7, 8 A growing body of evidence suggests that PCa in black men may be biologically different than in white men. Prostate tumors from black men have been shown to express higher levels of androgen receptor (AR) 9 and epidermal growth factor receptor 10 and contain a smaller number of CAG repeats in the AR gene 11 relative to white men. Furthermore, examination of gene expression profiles of prostate tumors revealed prominent difference in tumor immunobiology between black and white men, suggesting the existence of two distinct tumor microenvironments. 12 In a previous publication limited to men with adequate tissue and longitudinal follow-up data available, we identified six immunofluorescence (IF)-combined biometric features from the prostate needle biopsy that were associated with disease progression and subsequently developed a patient-specific, biology-driven tool to predict outcome at diagnosis. 13 The present study is a secondary analysis of a sub-population from that study. We sought to investigate whether the expression of these six biometric features of aggressive disease differs between populations of black and white men. These six features are derived from three distinct proteins: AR, Ki67 and a-methylacyl CoA racemase (AMACR). To the best of our knowledge, this is the first study to investigate racial differences in the expression of AMACR.
Materials and methods

Study population and sample analysis
After obtaining institutional review board approval from the Durham Veterans Affairs Medical Center (VAMC), data were collected from men treated with RP between 1989 and 2003 for localized or locally advanced (cT1-cT3) PCa. Men receiving preoperative hormone or radiation therapy were excluded from analysis. Within this time frame, we identified a cohort of 131 men for which formalin-fixed, paraffin-embedded prostate needle biopsy tissue samples were available as well as complete clinical and pathological data. As previously described, these biopsy specimens were hematoxylin and eosin stained and IF assayed for AR, AMACR and Ki67. 13 Proprietary quantitative multiplex IF assays and image analysis algorithms from Aureon Biosciences (Yonkers, NY, USA) was used to identify six significant IF features of PCa progression: relative area of tumor nuclei that stained positive for both AR and AMACR (AR & AMACR), relative area of tumor nuclei that stained positive for AR and AMACR divided by the lumen area (AR & AMACR/lum), normalized AR intensity in Gleason grade 3 tumor nuclei (Norm AR), dynamic AR intensity (dyn AR), relative area of tumor nuclei that stained positive for Ki67 (Ki67), and relative area of tumor nuclei that stained positive for Ki67 divided by the lumen area (Ki67/lum) (see ref. 13 for more details). These six combined biometric-clinical features were selected by Aureon Biosciences after a thorough analysis of a larger panel of available biometric feature profiles for their ability to significantly predict PCa outcomes. 13 
Statistical analysis
The Stata10 software package (StataCorp; College Station, TX, USA) was used for all statistical analysis. We analyzed baseline characteristics of the study population, stratified by race, using t-test, rank-sum, and w 2 -test as appropriate. We then analyzed the expression of these six IF biometric features from the prostate needle biopsy specimens as a function of race using multivariate linear regression, with the biomarker expression being the outcome variable and race being the predictor variable.
Analyses were mutually adjusted for the preoperative characteristics of age (continuous), PSA (continuous after logarithmic transformation), year of surgery (continuous) and biopsy Gleason score (p6, 3 þ 4 and X4 þ 3). All P-values were two-sided, with a threshold of Po0.05 for statistical significance.
Clinical and pathological variables
Race (black vs white) was abstracted from medical records, which had been originally entered when the patient first entered the VA health system based on selfreport. Patient age and year of surgery were defined at the time of RP and evaluated as continuous variables. Body mass index was abstracted from preoperative height and weight. PSA values were obtained from the measurement closest to the date of, but preceding, RP. Gleason score was obtained from the biopsy specimen and placed into one of three categories: p6, 3 þ 4 and X4 þ 3.
Results
Baseline characteristics of the study population are described in Table 1 . Of the 131 subjects, 67 (51%) were black and 64 (49%) were white. Mean age for black and white men was 62 and 64, respectively. Mean body mass index was 28.6 kg m À2 and 27.8 kg m À2 . Mean PSA was 7.7 ng ml À1 for both black and white men. The majority of men in both races had a biopsy Gleason score p3 þ 4. We found no significant difference between black and white men with regard to body mass index, PSA level and biopsy Gleason score (all P40.12).
When we analyzed biomarkers of aggressive disease (Table 2) , we found that all six IF biometric features were expressed at higher levels in black men compared with white men, with Norm AR (black ¼ 0.95, white ¼ 0.62, P ¼ 0.006) and Ki67 (black ¼ 0.05, white ¼ 0.03, P ¼ 0.02) attaining statistical significance. This association remained after multivariate adjustment for preoperative characteristics (Table 3) , with all six biometric features of aggressive disease being expressed at higher levels in black men. Norm AR (black ¼ 1.10, white ¼ 0.72, P ¼ 0.001), Ki67 (black ¼ 0.06, white ¼ 0.04, P ¼ 0.002) and Ki67/lum (black ¼ 0.63, white ¼ 0.38, P ¼ 0.004) reached statistical significance.
Discussion
In this analysis of prostate needle biopsy tissue from 131 men undergoing RP at the Durham VAMC, we compared the expression of six biometric features of aggressive disease in black vs white men. We found that all six features were expressed at higher levels in black men, with two attaining statistical significance. This association persisted after multivariate adjustment for preoperative characteristics, with three IF features reaching significance. These findings suggest cancers in black men, even at an early stage, may be more aggressive than among white men, though future larger studies with long-term outcome are needed to confirm these findings.
All men in our study underwent PSA screening at the Durham VAMC, an equal access setting, and were treated with aggressive surgical therapy after their tumors were identified. These selection criteria were intended to minimize the effect of treatment disparities on the observed differences in PCa outcome between black and white men.
Studies have shown that in the general population, black men are more likely to receive non-surgical therapy than white men with equivalent disease characteristics. 14 However, in equal access settings (that is, active military hospitals), black men tend to be treated with surgery at a similar rate as white men. 15 Furthermore, we previously reported that there is no significant difference with regards to ethnicity in the timing of surgical treatment Prostate biopsies from black men express higher levels of aggressive disease biomarkers HS Kim et al once PCa has been diagnosed within the equal access setting of VA hospitals. 16 These data support the hypothesis that, despite equal access to care and equally aggressive treatment, PCa in black men may be more biologically aggressive than PCa in white men. Our results confirm existing findings that prostate tumors from black men have an increased expression of AR, 9 which cannot be explained by differences in Gleason grade. Furthermore, to the best of our knowledge, we have demonstrated for the first time that prostate tumors in black men have an increased expression of AMACR, a key enzyme in branched-chain fatty acid metabolism, 17 and Ki67, a protein associated with cellular proliferation. Although Ki67 is a general marker of RNA transcription and cell proliferation, differential expression of AMACR may speak to alternate pathways of metabolism in tumors from black and white men. The exact role of AMACR in PCa biology remains unclear, however, one study found that AMACR expression has been shown to correlate with increased Gleason score. 18 Precisely how elevated expression of AMACR in tumors from black men leads to more aggressive disease or the implications of this finding for PCa prevention and therapy are not obvious. Future studies are needed to validate as well as to elucidate the biological relevance of this finding.
Our study was relatively small and thus subject to type 1 error. As a pilot study, we only used samples from our institution that had been included in a previous larger multicenter study designed to examine the relationship between these six IF markers and clinical outcome. As such, this study was limited to men with available follow-up, though the data for our specific center was too limited to examine the association with outcome. To better conclude racial differences in these IF markers, a larger study is needed. However, the consistency in our findings-that all IF markers were higher in black men with three reaching significance on multivariate analysis-argues against a spurious finding, though validation is required. Additionally, this study was underpowered to assess the association between race and outcome after treatment. However, a separate analysis of the larger SEARCH database-which includes men undergoing RP at several other VAMCs, including Durham-did reveal an increased risk of biochemical recurrence in black men compared with white men, which was slightly attenuated on multivariate analysis (HR 1.19, P ¼ 0.09). 19 Thus, whether higher expression of these markers accounts for the worse outcomes, remains to be tested. A corollary, which again due to limited power we were unable to test, is whether these markers are equally predictive of poor outcome in black and white men. In other words, is the clinical relevance of an elevated IF marker the same, regardless of race? Ultimately, larger studies are needed to address this question. Finally, we examined only prostate needle biopsy tissue and not final RP specimen for the expression of these aggressive disease biomarkers, raising the possibility that our biopsy sample was not representative of the entire tumor. However, as sampling from a needle biopsy is known not to perfectly correlate with the RP specimen, this limitation should have biased the results towards the null. As such, the differences in IF markers may have been even greater if examined in the RP specimens.
In this small retrospective study of prostate needle biopsy tissue from men at the Durham VAMC, we observed that tumors from black men expressed higher levels of six aggressive disease biometric features compared with tumors from white men. Our results confirm previous observations of increased AR expression in prostate tumors from black men. Furthermore, we present the novel finding that prostate tumors from black Prostate biopsies from black men express higher levels of aggressive disease biomarkers HS Kim et al men express higher levels of Ki67 and AMACR. These observations provide additional evidence that PCa in black men may be biologically different than PCa in white men, though larger studies are needed to confirm these findings.
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